Alexion Pharmaceuticals to acquire Syntimmune for $1.2bn to boost rare disease drug pipeline

In a significant move within the pharmaceutical industry, Alexion Pharmaceuticals, a leading global biopharma company, has announced its acquisition of Syntimmune, a Boston-based clinical-stage biotech ... Read More